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Introduction: Primary signet-ring cell carcinoma of the urinary bladder is a rare variant of mucus-producing
adenocarcinoma constituting approximately 0.5% to 2.0% of all primary carcinomas of the bladder. This tumor initially
presents as a high-grade, high-stage lesion and diffusely invades the bladder wall without forming intraluminal growth.
The patients have no specific symptoms, which leads to delayed diagnosis and poor prognosis.
Case presentation: We report the case of a 51-year-old Moroccan Berber man consulting for gross hematuria.
Ultrasonography and a computed tomography scan found a bladder tumor diffusely invading the bladder wall. A
histopathological examination of the tumor chips from a transurethral resection of the bladder revealed signet-ring cell
adenocarcinoma. The gastrointestinal tract exploration did not reveal any other tumor localization. A radical cystectomy
and adjuvant cisplatin and gemcitabine chemotherapy were therefore performed resulting in 18 months of survival
without metastasis and a good quality of life within that time.
Conclusion: The rarity and the successful management with carboplatin and gemcitabine as adjuvant chemotherapy
of this entity, which is rarely reported in the literature, are two remarkable characteristics described in this case report.
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Primary signet-ring cell carcinoma (PSRCC) is a rare
neoplasm of the urinary bladder. Less than 100 cases
were described after Saphir reported the first two cases
in 1955 [1]. We present one case of primary signet-ring
cell carcinoma of the urinary bladder with a brief review
of the current literature.
Case presentation
A 51-year-old Moroccan Berber man was referred to our
hospital with a history of three months of intermittent
painless total gross hematuria, frequency and urgency.
The medical and familial histories were unremarkable.
Ultrasonography revealed a grade II left hydronephrosis
and circumferential thickening of the urinary bladder* Correspondence: drahsaini@gmail.com
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distribution, and reproduction in any mediumwall. A computed tomography (CT) scan showed a dif-
fuse neoplasm of the urinary bladder with no lymph
node enlargement or distant metastases (Figure 1).
Cystoscopic examinations revealed nonpapillary sessile
tumors occupying almost the whole of the bladder wall
(Figure 2), and the left side of the trigone obstructing
the left ureteral meatus. Transurethral resection of
the lesion was realized incompletely because of the
diffuse character of the tumor. Histopathological spe-
cimen examination found a poorly differentiated mucin-
secreting adenocarcinoma of the signet-ring cell type
(Figure 3).
We performed a complete gastrointestinal endoscopic
evaluation and analysis of tumor markers to exclude an
extravesical primary tumor site, but no other primary
site was found. The tumor was therefore treated as a pri-
mary signet-ring cell carcinoma of the urinary bladder.
The patient underwent radical cystectomy with an
ileal conduit and bilateral pelvic lymphadenectomy.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Pelvic computed tomography showing an invasive
tumor of the urinary bladder.
Figure 3 Histopathology of the bladder lesion showing
multiple signet-ring cells in the lamina propria with overlying
transitional cell epithelium.
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reported adenocarcinoma composed of signet-ring cells
with an abundant mucin pool that was invading the perive-
sical adipose tissue and one lymph node (<2cm) staging the
tumor at pT3bN1M0. Adjuvant chemotherapy was then
performed with four cycles of cisplatin, a 100mg/m2 on
day 1 and gemcitabine 1000mg/m2 on days 1 and 8 com-
bination, every 21 days. The patient was followed up every
six months, and a thoracoabdominal CT scan was done
every six months. He was free from metastasis, the quality
of life was good without symptoms of pain or renal dys-
function, and he achieved weight recovery soon after finish-
ing his chemotherapy. Eighteen months postoperatively,
the patient presented with pelvic and back pain. Multiple
metastases to spine, lung and pelvis were noted on a thora-
coabdominal CT scan. The patient refused to be enrolled in
any additional protocol and died four months later due to
respiratory distress.Figure 2 Cystoscopic appearance showing multiple grape-like
lesions in the posterior wall of the urinary bladder.Discussion
Primary signet-ring cell carcinoma of the urinary bladder
is a relatively rare subtype of adenocarcinoma and com-
prises only 0.24% to 2% of all primary epithelial urinary
bladder tumors [2,3]. Less than 100 cases have been
reported in the literature since the first two cases
reported by Saphir in 1955 [1]. The histopathogenesis of
primary mucin-producing adenocarcinomas, including
signet-ring cell carcinomas, remains unclear, because the
normal bladder contains neither columnar nor mucus-
secreting glandular epithelium. Many investigators pro-
posed that the metaplastic potential of the urothelium
has two distinct patterns. Progressive invagination of
hyperplastic epithelial buds into the lamina propria (Von
Brunn’s nest) leads to the formation of cystitis cystica.
Subsequent metaplasia of the urothelial lining within
these cysts to columnar mucin-producing cells results in
the production of cystitis glandularis, which is a prema-
lignant lesion. Alternatively, cuboidal or columnar meta-
plasia of the surface epithelium can occur without
downward invagination, with chronic vesical irritation
and infection being the predisposing factors of these
changes. Most of these tumors are mucin-secreting but
the passage of mucus during micturition is uncommon.
Two-thirds of the tumors were mucin-secreting, in most
of which the site of the deposition was extracellular
(interstitial). Less commonly, mucin is secreted within
the lumen of the acini and infrequently, excessive intra-
cellular mucin displaces the nucleus to a peripheral cres-
cent, giving the cells a signet-ring appearance [4].
Generally, this neoplasm occurs in middle age and is
usually diagnosed at an advanced stage, usually demon-
strating a subsequently poor prognosis [5]. The usual
clinical presentation does not differ significantly from
that of other bladder malignancies [6]. The common
presenting symptoms were irritative voiding symptoms
and hematuria. Urinary retention and flank pain due to
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carcinomas of the bladder were most often infiltrative and
diffusely involving the majority of the bladder. The lesion
is described in cystoscopy as pedunculated, polypoid, ses-
sile, and ulceroinfiltrative [4]. Bladder adenocarcinoma
may arise in any region of the bladder but it is usually
found in the bladder dome [6]. It may be very difficult to
rule out because it has the same histological and immuno-
histochemical features as urachal carcinoma. Signet-ring
cells can also be found in adenocarcinomas of urachal ori-
gin. Several criteria for classifying a tumor as urachal in
origin have been suggested [2]: 1) tumor in the bladder
(dome), 2) a sharp demarcation between the tumor and
the surface epithelium, and 3) exclusion of primary adeno-
carcinoma located elsewhere that spread secondarily to
the bladder. The present case showed no sharp demarca-
tions between the tumor and the surface epithelium. Thus,
we could exclude an urachal tumor in origin.
It is essential to distinguish this carcinoma from metasta-
ses, as different therapeutic strategies are often necessary.
Primary signet-ring cell carcinoma of the urinary bladder
has the same histology as that of the gastrointestinal tract,
breast, lung, gallbladder, and prostate; therefore, further
evaluations for other primary sites are mandatory to ex-
clude metastasis [4,6]. In our case, the gastrointestinal
evaluation included esophagogastroduodenoscopy and col-
onoscopy, but we found no other tumor lesions. Although
there is no established serum marker of primary signet-
ring cell carcinoma of the urinary bladder, elevated carci-
noembryonic antigen (CEA) has often been reported.
Yamamoto et al. [4] reported that the serum level of CEA
is normalized postoperatively and gradually increases as
the disease progresses. They have suggested, therefore, that
CEA might be used for determining malignant potential
and for monitoring signet-ring cell carcinoma. In our case,
CEA elevation was not noted.
The prognosis is usually poor as it is usually diagnosed at
an advanced stage [1-7]. Treatment modalities for signet-
ring cell carcinomas include surgery, radiotherapy, and
chemotherapy. Surgical options range from transurethral
resection to radical cystectomy with urinary diversion.
According to the review by Erdogru et al. [7] only total
cystectomy might offer some hope for patients. Several ef-
fective treatments including intra-arterial chemotherapy
with cisplatin and methotrexate [8] and radiation therapy,
or only radiotherapy after cystectomy were reported in the
literature. Unfortunately, no standard chemotherapy exists
for PSRCCs of the bladder because of their rarity. We re-
port this case of PSRCC treated with total cystectomy fol-
lowed by systemic chemotherapy with cisplatin and
gemcitabine, a standard combination for transitional car-
cinoma of the urinary bladder, with a successful outcome
due to the time of survival without metastasis, which was
18 months, and 22 months before he died.Conclusion
Primary signet-ring cell carcinoma of the urinary bladder
is a rare histological variant of mucus-producing adeno-
carcinoma, which is generally high-grade, high-stage and
has a uniformly poor prognosis. Recently, successful
treatments with chemotherapy alone have been reported.
However, the appropriate regimen and the method of in-
jection have not yet been established. This case is unique
in using other kinds of chemotherapy (cisplatin and
gemcitabine) resulting in 18 months of survival without
metastasis.
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